文献速递临床试验与 GCP流行病学与生物统计

粪便免疫化学检测前单次服用阿司匹林对晚期结直肠肿瘤检测灵敏度的影响:一项随机临床试验

Effect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test Sensitivity for Detecting Advanced Colorectal Neoplasms: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

在德国14家胃肠病诊所和4家医院开展的随机、安慰剂对照、双盲试验,纳入2422名40至80岁计划接受结肠镜检查且未近期使用阿司匹林或其他抗血栓药物的受试者。粪便采样前2天单次口服300 mg阿司匹林或安慰剂,主要终点为定量粪便免疫化学检测在10.2和17 μg Hb/g粪便两个预设阈值下检测晚期肿瘤的灵敏度。阿司匹林组与安慰剂组灵敏度差异均未达统计学显著。

要点

  • 在10.2 μg Hb/g粪便阈值下,阿司匹林组灵敏度40.2%,安慰剂组30.4%,差异9.8%(95% CI,-3.1%至22.2%,P=0.14)。
  • 在17 μg Hb/g粪便阈值下,阿司匹林组灵敏度28.6%,安慰剂组22.5%,差异6.0%(95% CI,-5.7%至17.5%,P=0.32)。
  • 粪便免疫化学检测前单次口服阿司匹林与安慰剂相比,未显著提高两个预设阈值下检测晚期结直肠肿瘤的灵敏度。

核心结论

  • 在40至80岁未使用阿司匹林或其他抗血栓药物的成人中,粪便免疫化学检测前单次口服阿司匹林与安慰剂相比,未显著提高定量粪便免疫化学检测在两个预设阈值下检测晚期结直肠肿瘤的灵敏度。

研究设计与样本

  • 随机、安慰剂对照、双盲试验,在德国14家胃肠病诊所和4家医院开展,纳入2422名40至80岁计划接受结肠镜检查且未近期使用阿司匹林或其他抗血栓药物的男性和女性,入组时间为2013年6月至2016年11月,末次随访为2017年1月27日。
  • 干预为粪便采样前2天单次口服含300 mg阿司匹林的片剂(n=1208)或安慰剂(n=1214)。
  • 最终分析纳入2134名受试者,其中78%为初级筛查结肠镜检查,22%为诊断性结肠镜检查。

主要发现

  • 2422名随机化患者平均(SD)年龄59.6(7.9)岁,男性1219名(50%)。
  • 224名参与者(10.5%)检出晚期肿瘤,包括8名(0.4%)结直肠癌和216名(10.1%)晚期腺瘤。
  • 在10.2 μg Hb/g粪便阈值下,阿司匹林组灵敏度40.2%,安慰剂组30.4%,差异9.8%(95% CI,-3.1%至22.2%,P=0.14)。
  • 在17 μg Hb/g粪便阈值下,阿司匹林组灵敏度28.6%,安慰剂组22.5%,差异6.0%(95% CI,-5.7%至17.5%,P=0.32)。

关键数值与推荐

  • 主要终点为定量粪便免疫化学检测在10.2和17 μg Hb/g粪便两个预设阈值下检测晚期肿瘤(结直肠癌或晚期腺瘤)的灵敏度。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Fecal immunochemical tests for hemoglobin are widely used for colorectal cancer (CRC) screening. Observational studies suggested that sensitivity of fecal immunochemical tests for detecting advanced neoplasms could be increased by acetylsalicylic acid (aspirin), especially among men. OBJECTIVE: To evaluate the potential to increase sensitivity of fecal immunochemical tests by administering a single 300-mg oral aspirin dose 2 days before stool sampling. DESIGN, SETTING, AND PARTICIPANTS: A randomized, placebo-controlled, double-blind trial was conducted in 14 gastroenterology practices and 4 hospitals in Germany, and included 2422 men and women aged 40 to 80 years scheduled for colonoscopy, with no recent use of aspirin or other drugs with antithrombotic effects (enrollment from June 2013 to November 2016, and final follow-up January 27, 2017). INTERVENTIONS: Administration of a single tablet containing 300 mg of aspirin (n = 1208) or placebo (n = 1214) 2 days before fecal sampling for fecal immunochemical test. MAIN OUTCOME AND MEASURES: The primary outcome was sensitivity of a quantitative fecal immunochemical test at 2 predefined cutoffs (10.2 and 17-μg Hb/g stool) for detecting advanced neoplasms (colorectal cancer or advanced adenoma). RESULTS: Among 2422 randomized patients (mean [SD] age, 59.6 [7.9] years; 1219, 50%, men), 2134 were included in the analysis (78% for primary screening colonoscopy, 22% for diagnostic colonoscopy). Advanced neoplasms were identified in 224 participants (10.5%), including 8 participants (0.4%) with CRC and 216 participants (10.1%) with advanced adenoma. Sensitivity was 40.2% in the aspirin group and 30.4% in the placebo group (difference 9.8%, 95% CI, -3.1% to 22.2%, P = .14) at cutoff 10.2-μg Hb/g stool and 28.6% in the aspirin and 22.5% in the placebo group (difference 6.0%, 95% CI, -5.7% to 17.5%, P = .32) at cutoff 17-μg Hb/g stool. CONCLUSIONS AND RELEVANCE: Among adults aged 40 to 80 years not using aspirin or other antithrombotic medications, administration of a single dose of oral aspirin prior to fecal immunochemical testing, compared with placebo, did not significantly increase test sensitivity for detecting advanced colorectal neoplasms at 2 predefined cutoffs of a quantitative fecal immunochemical test. TRIAL REGISTRATION: Deutsches Register Klinischer Studien Identifier: DRKS00003252; EudraCT Identifier: 2011-005603-32/DE.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Brenner H, Calderazzo S, Seufferlein T, et al. Effect of a Single Aspirin Dose Prior to Fecal Immunochemical Testing on Test Sensitivity for Detecting Advanced Colorectal Neoplasms: A Randomized Clinical Trial. JAMA. 2019. PMID: 31063574. doi:10.1001/jama.2019.4755

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。